



SOMNOMED 2025 HALF-YEAR FINANCIAL RESULTS AND INVESTOR PRESENTATION

SomnoMed Limited (SomnoMed or the Company) (ASX: SOM) advises its H1FY25 Financial Results and Investor Presentation will be released to the ASX pre-market open on Friday 28th February 2025.

Following the release, management will host an investor presentation and Q&A session on the H1FY25 Results at 11am AEDT via a webinar.

Participants are invited to register for the webinar via the following link:

https://zoom.us/webinar/register/WN_OzrP09oTQW2YuA2dxms0IA

Once you have registered you will receive an email confirming your attendance and information about joining the webinar.

11th February 2025

This release has been approved by the Company Secretary of SomnoMed Limited

About SomnoMed

SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent[®] becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 940 000 patients in over 20 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>

For personal use only